These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 33970296)

  • 1. Prognostic association of medication trajectories with 3-year mortality in heart failure and preserved ejection fraction: findings from the EPICAL2 cohort study.
    Bitar S; Thilly N; Agrinier N
    Eur J Clin Pharmacol; 2021 Oct; 77(10):1569-1581. PubMed ID: 33970296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
    Martin N; Manoharan K; Thomas J; Davies C; Lumbers RT
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD012721. PubMed ID: 29952095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
    Martin N; Manoharan K; Davies C; Lumbers RT
    Cochrane Database Syst Rev; 2021 May; 5(5):CD012721. PubMed ID: 34022072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of heart failure pharmacotherapies in patients with heart failure with mildly reduced ejection fraction.
    Schupp T; Bertsch T; Reinhardt M; Abel N; Schmitt A; Lau F; Abumayyaleh M; Akin M; Weiß C; Weidner K; Behnes M; Akin I
    Eur J Prev Cardiol; 2024 Aug; 31(11):1347-1360. PubMed ID: 38513366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Prescribing Patterns of Renin-Angiotensin System Blockers and Beta-Blockers on Prognosis of Heart Failure.
    Kim HJ; Jo SH; Lee MH; Seo WW; Choi JO; Ryu KH
    Adv Ther; 2020 Sep; 37(9):3839-3849. PubMed ID: 32676928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence to ESC guideline-recommended medications over a 36-month follow-up period after hospitalization for heart failure: Results from the EPICAL2 cohort study.
    Bitar S; Agrinier N; Alla F; Rossignol P; Mebazaa A; Thilly N
    Pharmacoepidemiol Drug Saf; 2019 Nov; 28(11):1489-1500. PubMed ID: 31339629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heart failure medication after a first hospital admission and risk of heart failure readmission, focus on beta-blockers and renin-angiotensin-aldosterone system medication: A retrospective cohort study in linked databases.
    Kruik-Kollöffel WJ; van der Palen J; Doggen CJM; van Maaren MC; Kruik HJ; Heintjes EM; Movig KLL; Linssen GCM
    PLoS One; 2020; 15(12):e0244231. PubMed ID: 33351823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities.
    Albert NM; Tyson RJ; Hill CL; DeVore AD; Spertus JA; Duffy C; Butler J; Patterson JH; Hernandez AF; Williams FB; Thomas L; Fonarow GC
    Am Heart J; 2021 May; 235():82-96. PubMed ID: 33497697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guideline-directed medical therapy in severe heart failure with reduced ejection fraction: An analysis from the HELP-HF registry.
    Tomasoni D; Pagnesi M; Colombo G; Chiarito M; Stolfo D; Baldetti L; Lombardi CM; Adamo M; Maggi G; Inciardi RM; Loiacono F; Maccallini M; Villaschi A; Gasparini G; Montella M; Contessi S; Cocianni D; Perotto M; Barone G; Merlo M; Cappelletti AM; Rosano G; Sinagra G; Pini D; Savarese G; Metra M
    Eur J Heart Fail; 2024 Feb; 26(2):327-337. PubMed ID: 37933210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Traditional Heart Failure Therapies in Patients With Cardiac Amyloidosis and Heart Failure.
    Yan CL; Gallo RA; Vasquez Martinez M; Rivera Rodriguez B; Trujillo L; Thakkar Rivera N; Hoffman JE
    Am J Cardiol; 2023 Oct; 204():360-365. PubMed ID: 37573615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction.
    Lund LH; Benson L; Dahlström U; Edner M
    JAMA; 2012 Nov; 308(20):2108-17. PubMed ID: 23188027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of guideline-consistent heart failure drug prescriptions at hospital discharge on 1-year mortality: Results from the EPICAL2 cohort study.
    Busson A; Thilly N; Laborde-Castérot H; Alla F; Messikh Z; Clerc-Urmes I; Mebazaa A; Soudant M; Agrinier N
    Eur J Intern Med; 2018 May; 51():53-60. PubMed ID: 29305071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of angiotensin receptor blocker at discharge in patients with heart failure with reduced ejection fraction: Korean Acute Heart Failure (KorAHF) registry.
    Choi KH; Lee GY; Choi JO; Jeon ES; Lee HY; Cho HJ; Lee SE; Kim MS; Kim JJ; Hwang KK; Chae SC; Baek SH; Kang SM; Choi DJ; Yoo BS; Kim KH; Park HY; Cho MC; Oh BH
    Int J Cardiol; 2018 Apr; 257():168-176. PubMed ID: 29506690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modern heart failure treatment is superior to conventional treatment across the left ventricular ejection spectrum: real-life data from the Swedish Heart Failure Registry 2013-2020.
    Karlström P; Pivodic A; Dahlström U; Fu M
    Clin Res Cardiol; 2024 Sep; 113(9):1355-1368. PubMed ID: 39186181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gap between guidelines and clinical practice in heart failure with reduced ejection fraction: Results from TSOC-HFrEF registry.
    Chang HY; Wang CC; Wei J; Chang CY; Chuang YC; Huang CL; Chong E; Lin JL; Mar GY; Chan KC; Kuo JY; Wang JH; Chen ZC; Tseng WK; Cherng WJ; Yin WH
    J Chin Med Assoc; 2017 Dec; 80(12):750-757. PubMed ID: 29033112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Pharmacologic and Cardiac Implantable Electronic Device Therapies in Patients With Heart Failure and Reduced Ejection Fraction: A Systematic Review and Network Meta-Analysis.
    Tseng AS; Kunze KL; Lee JZ; Amin M; Neville MR; Almader-Douglas D; Killu AM; Madhavan M; Cha YM; Asirvatham SJ; Friedman PA; Gersh BJ; Mulpuru SK
    Circ Arrhythm Electrophysiol; 2019 Jun; 12(6):e006951. PubMed ID: 31159582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renin-Angiotensin System Inhibition and Lower 30-Day All-Cause Readmission in Medicare Beneficiaries with Heart Failure.
    Sanam K; Bhatia V; Bajaj NS; Gaba S; Morgan CJ; Fonarow GC; Butler J; Deedwania P; Prabhu SD; Wu WC; White M; Love TE; Aronow WS; Fletcher RD; Allman RM; Ahmed A
    Am J Med; 2016 Oct; 129(10):1067-73. PubMed ID: 27262781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of clinical characteristics and management on the prognosis of unselected heart failure patients.
    Eschalier R; Chenaf C; Mulliez A; Yalioua A; Clerfond G; Authier N; Vorilhon C; Citron B; Pereira B; Jean F; Souteyrand G; Motreff P; Eschalier A; Lusson JR
    Cardiovasc Drugs Ther; 2015 Feb; 29(1):89-98. PubMed ID: 25700624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF.
    Beusekamp JC; Tromp J; van der Wal HH; Anker SD; Cleland JG; Dickstein K; Filippatos G; van der Harst P; Hillege HL; Lang CC; Metra M; Ng LL; Ponikowski P; Samani NJ; van Veldhuisen DJ; Zwinderman AH; Rossignol P; Zannad F; Voors AA; van der Meer P
    Eur J Heart Fail; 2018 May; 20(5):923-930. PubMed ID: 29327797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of renin-angiotensin-aldosterone system inhibition on morbidity and mortality during long-term continuous-flow left ventricular assist device support: An IMACS report.
    Brinkley DM; Wang L; Yu C; Grandin EW; Kiernan MS
    J Heart Lung Transplant; 2021 Dec; 40(12):1605-1613. PubMed ID: 34663529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.